by Sean Hutchinson | Jul 23, 2026 | UK
In 2017, the UK Supreme Court issued a landmark judgment setting out how it believed the UK should apply the so-called “doctrine of equivalents” when deciding on infringement of a patent. This judgment was handed down in the case of Actavis v Eli Lilly and the test...
by Alyson Lam | Jul 14, 2026 | US & International
Overview Broad antibody claims have faced a difficult path in the US since Amgen v Sanofi, particularly where the claim covers a large functional genus. The Federal Circuit’s decision in Teva v Eli Lilly is therefore interesting because the court drew an important...
by Sean Hughes | Jun 22, 2026 | EPO
Admissibility: Should the Enlarged Board Answer at All? The first question in G 1/26 is procedural. The referring Board asks whether a referral is “required” under Article 112(1) EPC where the legal issue arises in the pending case but the Board has not...
by Agne Augustinaite | Jun 16, 2026 | UPC
Background The Claimant, Agathon, was the proprietor of a European patent relating to a mechanical system designed to improve alignment in industrial machinery. Particularly, the invention concerns the repeated opening and closing of heavy metal components where...
by Sean Hutchinson | May 19, 2026 | UPC
Background: Long-Arm Jurisdiction The Unified Patent Court (“UPC”) was introduced as a central forum for enforcing European patents across the European Union (“EU”). However, not all EU Member States (e.g. Spain) signed up to the UPC Agreement (“UPCA”), and some...
Recent Comments